Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 16/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111589 | 0.93 | MEN1 (0.49) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL3954172 | 0.90 | MEN1 (0.52) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL932213 | 0.88 | MEN1 (0.52) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL3947403 | 0.87 | SMN1; SMN2 (0.36) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL2357881 | 0.86 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL7742082 | 0.86 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5285827 | 0.85 | MEN1 (0.65) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL3954819 | 0.84 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL28478541 | 0.84 | MEN1 (0.65) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL4023088 | 0.84 | MEN1 (0.65) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772438-B2 | Preparation of polyamides | Invista North America S.är.l. (US) | 2014-07-08 | — | — | US | claimed |
| US-20120264907-A1 | PREPARATION OF POLYAMIDES | INVISTA NORTH AMERICA S.A.R.L. (US) | 2012-10-18 | — | — | US | claimed |
| EP-2451863-A1 | PREPARATION OF POLYAMIDES | Invista Technologies S.A R.L. (CH) | 2012-05-16 | — | — | EP | claimed |
| WO-2011004138-A1 | PREPARATION OF POLYAMIDES | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2011-01-13 | — | — | WO | claimed |
| US-8772438-B2 | Preparation of polyamides | Invista North America S.är.l. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120264907-A1 | PREPARATION OF POLYAMIDES | INVISTA NORTH AMERICA S.A.R.L. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2451863-A1 | PREPARATION OF POLYAMIDES | Invista Technologies S.A R.L. (CH) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004138-A1 | PREPARATION OF POLYAMIDES | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2011-01-13 | — | — | WO | disclosed |
| EP-2051788-A1 | EXTRACTION PROCESS USING AN IONIC LIQUID | Invista Technologies S.à.r.l. (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-7442841-B2 | Extraction process | INVISTA NORTH AMERICA S.A R.L. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080051609-A1 | EXTRACTION PROCESS | INVISTA NORTH AMERICA S.A.R.L. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008022233-A1 | EXTRACTION PROCESS USING AN IONIC LIQUID | INVISTA TECHNOLOGIES S.A.R.L. (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051609-A1 | EXTRACTION PROCESS | ADH1C, ADH1A, ADH5 | MEN1 3505/4885HSP90AA1 2950/4885KMT2A 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.